Cagrilintide

Cagrilintide is an investigational, long-acting analogue of the pancreatic hormone amylin. Research has focused on appetite regulation, gastric emptying, energy intake, and its use in combination with incretin-based agents.

Acts primarily at amylin and calcitonin-family receptors in the central nervous system and gastrointestinal axis, where amylin signaling is associated with satiety and meal-size regulation.

Meaningful human investigation; multiple clinical studies exist, including combination studies with semaglutide.

Level II, Meaningful human investigation

The molecule remains investigational. Published results from sponsor-controlled trials do not establish the identity, quality, safety, or equivalence of independently manufactured research material.

Reported clinical-study effects have commonly involved gastrointestinal symptoms and reduced appetite. Long-term safety and combination effects remain under investigation.

Investigational; no FDA-approved drug product containing cagrilintide.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• Cagrilintide, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.